他达拉非5 mg对下尿路症状男性排尿后滴沥的影响:多中心、双盲、随机、安慰剂对照试验
这项前瞻性、随机、双盲、安慰剂对照、多中心试验纳入102例伴排尿后滴沥(PMD)及其他下尿路症状(LUTS)的男性,比较每日一次他达拉非5 mg(n=51)与安慰剂(n=51)治疗12周的效果。他达拉非组HPMDQ总分改善及PMD体积减少均显著优于安慰剂组,且未发生严重不良事件,提示其可能为有效且耐受良好的PMD治疗。
要点
- 他达拉非5 mg组HPMDQ总分降低≥2分的患者比例为68.8%,安慰剂组为31.9%(P < 0.001)。
- 他达拉非组平均PMD体积减少0.48 mL,安慰剂组减少0.22 mL(P = 0.046)。
- 治疗期间不良事件两组无显著差异(所有P > 0.05),未观察到严重不良事件。
核心结论
- 每日一次他达拉非5 mg较安慰剂更有效减轻PMD症状严重程度和PMD体积,且未引起严重不良事件,提示其可能为有效且耐受良好的PMD治疗。
研究设计与样本
- 前瞻性、随机、双盲、安慰剂对照、多中心试验,纳入102例伴PMD及其他LUTS的男性,他达拉非5 mg组(n=51)与安慰剂组(n=51)每日一次治疗12周。
主要发现
- 12周内他达拉非组HPMDQ总分降低≥2分的患者比例为68.8%,安慰剂组为31.9%(P < 0.001)。
- 他达拉非组平均PMD体积减少0.48 mL,安慰剂组减少0.22 mL(P = 0.046)。
- 他达拉非组PMD频率下降及生活质量提高均显著优于安慰剂组(P = 0.029和P < 0.001)。
- 他达拉非组66.7%报告PMD中度及显著改善,仅4.2%报告他达拉非无效。
- 治疗期间不良事件两组无显著差异(所有P > 0.05),未观察到严重不良事件。
临床怎么用
- 原文结论提示每日一次他达拉非5 mg可能为有效且耐受良好的PMD治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the effects of taking tadalafil 5 mg and placebo once daily on post-micturition dribble (PMD) in men with lower urinary tract symptoms (LUTS). PATIENTS AND METHODS: Our prospective, randomized, double-blind, placebo-controlled, multicentre trial enrolled 102 men with PMD and other LUTS. PMD was assessed using the Hallym Post-Micturition Dribble Questionnaire (HPMDQ) and according to PMD volume. Over a 12-week period, patients took either tadalafil 5 mg (n = 51) or placebo (n = 51) once daily and their HPMDQ and PMD volume results were evaluated. Adverse events (AEs) were also reported. RESULTS: Over the course of 12 weeks, total HPMDQscores and PMD volumes improved significantly more in the tadalafil group than in the placebo group (reduction of total HPMDQ score of ≥2 points in the tadalafil and placebo group in 68.8% and 31.9% of patients (P < 0.001) and decreased mean PMD volume in the tadalafil and placebo group at 0.48 mL and 0.22 mL, respectively (P = 0.046). Specifically, PMD frequency decreased and quality of life increased significantly more in the tadalafil group than in the placebo group (P = 0.029 and P < 0.001, respectively). Furthermore, 66.7% of the tadalafil group reported moderate and significant PMD improvement, whereas only 4.2% reported that tadalafil was ineffective. Treatment-emergent AEs did not significantly differ between the groups (all P > 0.05), and no serious AEs were observed. CONCLUSION: Taking tadalafil 5 mg once daily reduced PMD symptom severity and PMD volume in men with PMD, without inducing serious AEs, more effectively than placebo, suggesting that taking tadalafil 5 mg once daily may be an effective and well-tolerated PMD treatment.
引用
- Yang DY, Jeong HC, Ko K, et al. Effect of tadalafil 5 mg on post-micturition dribble in men with lower urinary tract symptoms: a multicentre, double-blind, randomized, placebo-controlled trial. BJU Int. 2019. PMID: 31207030. doi:10.1111/bju.14849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。